Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intrexon, a synthetic biology company, has acquired Immunologix, which focuses on transforming naive B-cells into human monoclonal antibodies.
Subscribe to our email newsletter
Immunologix has developed mAbLogix platform, which enables the ability to derive fully human antibodies.
The antibodies target all antigen types including, cancer cells, viruses, bacteria, toxins, as well as epitopes related to autoimmune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis.
Terms of the acquisition, however, have not been disclosed.